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Abstract
We report a patient with dermatomyositis (DM) complicated with progressive pleural effusion and 
ascites. A 40-year-old woman was hospitalized in our department because of severe myalgia and 
dysphagia, complicated with pleural effusion and massive ascites. Elevated muscle enzymes, Got-
tron’s papules, and electromyography (EMG) confirmed the diagnosis of DM. Combined immuno-
suppressive treatment consisting of intravenous immunoglobulin (IV-IG), intravenous-cyclophos-
phamide (IV-CY) and tacrolimus resolved her myopathy and dysphagia as well as pleural effusion 
and massive ascites. Her clinical course and the absence of other factors that cause pleural effusion 
and ascites suggest that these symptoms were related to the pathophysiology of DM.
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Introduction
Polymyositis-dermatomyositis (PM-DM) is a 
chronic inflammatory disorder that involves muscle 
and skin1). Many cases of PM-DM are associated 
with internal malignancies and interstitial lung dis-
ease2). In contrast to the frequent association of in-
terstitial lung disease (ILD) in patients with DM, the 
development of pleural effusion and ascites in DM is 
regarded as rare and there is little information re-
garding their incidence, etiology, course, and prog-
nosis3,4). Therefore, it could be difficult to differen-
tiate these cases due to DM from those due to other 
cases, including infections and malignancies. We 
herein report a female with DM complicated by 
pleural effusion and massive ascites. These condi-
tions appear to be signs of her severe primary auto-
immune disorder, DM. We hypothesize on the 
mechanisms behind the accumulating effusion and 
the therapeutic effect of immunosuppression in this 
unusual subset of DM.
Case report
A 40-year-old Japanese female was transferred 
to our hospital with severe myalgia and dyspha-
gia. Previously admitted to a local hospital for ele-
vated levels of muscle enzyme, she developed dys-
phagia and muscle weakness and transferred to our 
care for further evaluation. She had never smoked 
and had no significant past medical history. Com-
puted tomography (CT) showed pleural effusion and 
massive ascites without evidence of internal malig-
nancy or interstitial lung disease. The patient had 
skin lesions characteristic of dermatomyositis, 
which included facial erythema and Gottron’s pap-
ules (Figure 1). Laboratory tests (Table 1) revealed 
a white blood cell (WBC) count of 6,000/μL (neutro-
phils 79%, lymphocytes 10%, and monocytes 10%), 
total protein 5.3 g/dL, albumin 2.7 g/dL, creatine ki-
nase (CK) 2,613 U/L, lactate dehydrogenase (LDH) 
543 U/L, C-reactive protein 0.05 mg/dL, ferritin 297 
ng/mL, KL-6 567 U/mL, TSH 1.41 μU/mL, Free T4 
(FT4) 0.86 ng/dL, Free T3 (FT3) 0.94 pg/mL. FT4 
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Table 1. Laboratory Findings on Admission
Peripheral blood  ANA 1 : 80 (<×160)
 Red blood cells 537×104/μL  Anti-ds-DNA Ab (−) (<9.9)
 Hemoglobin 15.8 g/dL  Anti-sm Ab (−) (<6.9)
 Hematocrit 48.0%  Anti-U1RNP Ab (−) (<4.9)
 Platelet 17.0×104/μL  Anti-SSA Ab (−) (<6.9)
 White blood cells 6,000/μL  Anti-SSB Ab (−) (<6.9)
  Neutrophil 79.0%  Anti-Jo-1 Ab (−) (<6.9)
  Eosinophil 0.0%  Anti-MDA5 Ab (−) (<32)
  Monocyte 10.0%  Anti-ARS Ab (−) (<24.9)
  Lymphocyte 10.0%  Anti-TIF1-γ Ab (−) (<32)
  Basophil 1.0%  Anti-Mi-2 Ab (−) (<53)
Blood chemistry  HBs-Ag (−)
 Total protein 5.3 g/dL (6.6-8.1)  HCV-Ab (−)
 Total bilirubin 0.6 mg/dL (0.4-1.5)  HIV-AgAb (−)
 Albumin 2.7 g/dL (4.1-5.1)  Tuberclosis specific interferon γ (−)
 Aspartate transaminase 150 U/L (13-33)  sIL-2R 725 U/ml (121-613)
 Alanine transaminase 76 U/L (8-42)  CEA 1.3 ng/ml (0.0-5)
 Lactate dehydrogenase 543 U/L (260-119)  CA19-9 13.9 U/ml (0.0-37)
 Alkaline phosphatase 150 U/L (80-250)  CA-125 57 U/ml (0.0-35)
 Creatine kinase 2,613 U/L (62-287)  CA15-3 26 U/ml (0.0-31)
 Aldolase 19.8 U/L (2.7-7.5) Urinalysis
 Myoglobin 676 ng/mL (0.0-60)  pH 6.5
 Blood urea nitrogen 13.0 mg/dL (8-20)  S.G. 1.026
 Creatinine 0.43 mg/dL (0.46-0.79)  U-protein (1+)
 Na 128 mEq/L (138-145)  U-bacterium (1+)
 K 4.0 mEq/L (3.6-4.8)  U-red blood cells 0-1/HPF
 Cl 96 mEq/L (101-108)  U-white blood cells 1-4/HPF
Serological tests  hyalin cast 0-1/HPF
 C-reactive protein 0.05 mg/dL (<0.30) Ascites
 Erythrocyte sedimentation rate 4 mm/hr (<15)  Total protein 2.9 g/dL
 Ferritin 297 ng/ml (12-60)  Albumin 1.8 g/dL
 IL-6 43.9 pg/ml (0.1-1.9)  Lactate dehydrogenase 307 U/L
 VEGF 39 pg/ml (11.4-270)  Glucose 159 mg/dL
 KL-6 567 U/ml (0.0-499)  Cytology class I
 IgG 763 mg/dL (870-1,700)  Culture negative
 IgA 141 mg/dL (110-410)
 IgM 162 mg/dL (35-220)
 C3 83 mg/dL (65-135)
 C4 33 mg/dL (13-35)
 TSH 1.41 μU/mL (0.5-5.0)
 FT4 0.86 ng/dL (0.90-1.70)
 FT3 0.94 pg/mL (2.30-4.00)
Abbreviation : IL-6 ; Interleukin-6, VEGF ; Vascular Endothelial Growth Factor, sIL-2R ; soluble interleukin-2 re-
ceptor, TSH ; thyroid stimulating hormone, FT3 ; free thyroid 3, FT4 ; free thyroid 4, ANA ; antinuclear antibodies, 
Ab ; antibody, MDA5 ; melanoma differentiation-associated gene 5, ARS ; aminoacyl-tRNA synthetase, TIF1-
γ ; transcriptional intermediary factor 1-γ, HIV AgAb ; Human Immunodeficiency Virus antigen antibody, 
HBsAg ; hepatitis B virus surface antigen, HCVAb ; hepatitis C virus antibody, CEA ; carcinoembryonic antigen, 
CA19-9 ; carbohydrate antigen 19-9, CA125 ; carbohydrate antigen 125, CA15-3 ; carbohydrate antigen 15-3, S.G. ; 
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and FT3 were slightly low, consistent with euthyroid 
sick syndrome. The patient was negative for the 
presence of anti-nuclear antibody (ANA ; titer 
1 : 80) and other autoantibodies, including anti-dou-
ble-stranded DNA (anti-dsDNA) antibody, anti-Jo-1 
antibody, anti-ARS antibody, anti-MDA5 antibody, 
and anti-TIF1-γ antibody. The panel of autoanti-
bodies was examined using immunoblotting (Euro-
line autoimmune inflammatory myopathies 16Ag, 
Euroimmun, Luebeck, Germany), with only anti-
PM/Scl-75 antibodies being weakly positive. How-
ever, no scleroderma symptoms were evident in this 
patient, who was negative for anti-Scl-70 antibody.
In addition, negative results were obtained for 
the presence of tumor markers, including carcino-
embryonic antigen (CEA), carbohydrate antigen 
19-9 (CA19-9), carbohydrate antigen 125 (CA125) 
and carbohydrate antigen 15-3 (CA15-3). Abdomi-
nocentesis revealed exudative ascites with no evi-
dence of infections or malignancy. Biochemical 
analysis revealed the following results : TP 2.9 g/
dL, LDH 307 U/mL, glucose 159 mg/dL, and culture 
was negative. An echocardiogram demonstrated 
normal left ventricular ejection fraction, normal left 
ventricular wall thickness without pericardial effu-
sion, and normal right heart function. Electromy-
ography revealed typical myopathic patterns : poly-
phasic and low-amplitude motor unit action 
potential. MRI showed an increased signal on axial 
short TI inversion recovery (STIR) images, most 
prominent in the proximal lower limbs (Figure 2). 
The patient fulfilled the diagnostic criteria for 
DM articulated by Bohan and Peter5,6) in the pres-
ence of typical skin manifestations, elevated muscle 
enzymes, muscle weakness, and myogenic pattern 
of electromyography (EMG) ; therefore, muscle bi-
Fig. 1. Cutaneous findings on admission.
  Gottoron’s papules on the back of both hands were observed.
Fig. 2. Magnetic resonance imaging (MRI) of the lower limbs on admission.
 Axial short TI inversion recovery (STIR) images showed high signal density in the affected proximal lower limbs 
(white arrow).
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opsy was omitted. The clinical course is shown in 
Figure 3. Our patient received intravenous methyl 
prednisolone pulse therapy (1,000 mg/day, 3 days). 
The treatment was followed by oral prednisolone (60 
mg/day), without significant improvement in the my-
ositis, muscle weakness, pleural effusion and asci-
tes. Therefore, she was given intravenous immu-
noglobulin (IV-IG, 400 mg/kg, 5 consecutive days), 
followed by IV-CY (cyclophosphamide 750 mg), 
which resulted in remission of the myositis and im-
provement of the muscle weakness and dyspha-
gia. This was followed by oral prednisolone (40 
Fig. 3. Clinical course of the patient. 
 mPSL : methyl prednisolone, PSL : prednisolone, Tac : tacrolimus, IV-CY : high-dose intravenous cyclophos-
phamide, IV-IG : high-dose intravenous immunoglobulin, CK : creatine kinase, CT : computed tomography
Fig. 4. Changes of ascites and pleural effusions detected by computed tomography (CT) during the clinical course 
(Day 4, Day 12, Day 54).
 With immunosuppressive therapy, ascites and pleural effusions disappeared by Day 54.
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mg/day) and tacrolimus (3 mg/day). With these 
treatments, the pleural effusion and massive ascites 
resolved and the clinical manifestations including 
myositis and skin lesions improved. During treat-
ment with PSL intermittent IV-CY therapy, creatine 
kinase (CK) decreased to within the reference inter-
val, and remained there as. PSL was gradually ta-
pered. There was no recurrence of pleural effu-
sions or ascites (Figure 4) and the patient was 
discharged at Day 70.
Discussion 
Pleural effusion associated with connective tis-
sue disease (CTD) is common in patients with rheu-
matoid arthritis (RA) and systemic lupus erythema-
tosus (SLE)7), whereas overt pleural effusion and 
ascites are rarely reported in patients with PM-
DM8). The lung is the most commonly affected ex-
tra-muscular organ in DM9), whereas pleural compli-
cations are rare and the pathology of these 
complications has not been extensively investigated. 
Our case report is of a patient with DM in whom 
pleural effusion and ascites were resolved by combi-
nation therapy consisting of corticosteroid and im-
munosuppressive agents. 
Owing to the fact that DM is often associated 
with malignancies10), it is necessary to perform tho-
racentesis or peritoneal tap in DM patients with 
pleural effusion or ascites. In the present case, cy-
tological analysis for malignancy was negative. 
Other causes, such as congestive heart failure, hy-
pothyroidism, malignancy, and renal insufficiency, 
were ruled out in our case. With the frequency of 
aspiration pneumonia due to respiratory muscle 
weakness9), it is difficult to determine the etiology of 
pleural effusion in DM. 
In the present case, analyses for infectious 
causes were negative. Although we could not com-
pletely rule out the possibility of infection, we con-
cluded that this was unlikely since our patient re-
sponded well to steroid and immunosuppressant 
without antibiotics. In parallel with the clinical im-
provement of the myositis, the patient’s pleural effu-
sion and ascites also resolved rapidly.
Clinically important pleural effusion or ascites 
have rarely been reported in patients with DM. 
An immune mechanism appears to have been 
an important cause of the pleural effusion and asci-
tes in the current case, since there was a prompt re-
sponse to immunosuppressive treatment after me-
ticulous workup for other etiologies. 
Pleural effusion in PM-DM has not been re-
ported as an isolated finding, but only in association 
with ILD11). In the present case, serum KL-6 was 
slightly high, but CT findings didn’t suggest pres-
ence of ILD. Others have reported that KL-6 is 
not only a serum marker for ILD but also has a puta-
tive role in the development of ILD onset12) ; there-
fore, we should pay attention to the development of 
ILD.
Lakhanpal et al. reported that none of 65 pa-
tients with PM (n=24) or DM (n=41) had pleural 
effusions clinically or at autopsy, although histologi-
cal evidence of fibrinous pleuritis was occasionally 
seen13), but the mechanisms underlying dermatomy-
ositis with effusion are still unclear. 
We conclude that dermatomyositis caused the 
pleural effusion and ascites because other cases of 
exudative ascites were ruled out clinically, and there 
was an obvious response to immunosuppressive 
therapy.
Previous reports suggested that autoimmunity 
associated with underlying inflammatory myopathy 
was potentially an important cause of pleural effu-
sion14). In patients with RA or SLE, circulating im-
mune complexes localized in the serosal capillaries 
appear to activate the complement system, which 
induces endothelial injury and subsequent capillary 
permeability15). An important feature of the pleural 
affectation in rheumatic disease is high capillary per-
meability15). The observation of elevated vascular 
endothelial growth factor (VEGF), which contributes 
to the increased vascular permeability in some cases 
of seronegative symmetrical synovitis with edema 
(RS3PE) or TAFRO syndrome16,17), prompted us to 
investigate VEGF in our case of DM, with a negative 
result. An immune mechanism appears to have 
been an important cause of the effusion in this case, 
given the good response to immunosuppressive 
treatments. The role of autoimmunity associated 
with underlying ILD or DM has been postulated to 
be an important cause of pleural effusion in DM18). 
The presence of anti-nuclear antibody is described 
in edema or pleural effusion19), whereas myositis-
specific autoantibodies have not been investigat-
ed. In our case, neither anti-nuclear antibody nor 
myositis-specific autoantibodies were detected. 
Therefore, the clinical phenotype of DM with pleural 
effusion and massive ascites could not be clari-
fied. Further studies are warranted in order to gain 
a better understanding of the pathophysiology and to 
develop a therapeutic approach for pleural effusion 
and ascites, which seems to be a rare complication 
of DM.
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In conclusion, the presentation of DM with 
pleural effusion and ascites is a rare clinical pheno-
type that is noteworthy because such cases are as-
sociated with significant morbidity. We need to be 
aware that pleural effusion and ascites may be the 
first presenting features of DM. Although there 
was a significant response to steroid and immuno-
suppressive treatments in our case, further informa-
tion is needed to clarify the optimal treatment of 
these patients and elucidate the underlying patho-
genesis of these conditions.
Conflict of interest
KM has received research grants from Chugai, 
Pfizer, and AbbVie. The rest of the authors declare 
that they have no competing interests
References
 1. Dalakas MC, Hohlfeld R. Polymyositis and der-
matomyositis. Lancet, 362 : 971-982, 2003.
 2. Fathi M, Lundberg IE. Interstitial lung disease in 
polymyositis and dermatomyositis. Curr Opin 
Rheumatol, 17 : 701-706, 2005.
 3. Wu Y, Chhaya S, Hurowitz B, et al. Clinically 
Amyopathic Dermatomyositis Complicated by 
Pleural Effusion Case Report, Literature Review, 
and Proposed Mechanism. Bull Hosp Jt Dis, 
73 : 217-220, 2015.
 4. Ota S, Kasahara A, Yamada T, et al. Dermatomyo-
sitis with massive ascites. Rheumatol Int, 
27 : 877-879, 2007.
 5. Bohan A, Peter JB. Polymyositis and dermatomy-
ositis (first of two parts). N Engl J Med, 292 : 
344-347, 1975.
 6. Bohan A, Peter JB. Polymyositis and dermatomy-
ositis (second of two parts). N Engl J Med, 292 : 
403-407, 1975.
 7. Bouros D, Pneumatikos I, Tzouvelekis A. Pleural 
involvement in systemic autoimmune disorders. 
Respiration, 75 : 361-371, 2008.
 8. Fathi M, Lundberg IE, Tornling G. Pulmonary 
complications of polymyositis and dermatomyosi-
tis. Semin Respir Crit Care Med, 28 : 451-458, 
2007.
 9. Kalluri M, Oddis CV. Pulmonary manifestations 
of the idiopathic inflammatory myopathies. Clin 
Chest Med, 31 : 501-512, 2010.
10. Yazici Y, Kagen LJ. The association of malignancy 
with myositis. Curr Opin Rheumatol, 12 : 498-
500, 2000.
11. Highland KB, Heffner JE. Pleural effusion in in-
terstitial lung disease. Curr Opin Pulm Med, 
10 : 390-396, 2004.
12. Ohnishi H, Yokoyama A, Kondo K, et al. Compar-
ative study of KL-6, surfactant protein-A, surfac-
tant protein-D, and monocyte chemoattractant pro-
tein-1 as serum markers for interstitial lung 
diseases. Am J Respir Crit Care Med, 165 : 378-
381, 2002.
13. Lakhanpal S, Lie JT, Conn DL, Martin WJ 2nd.    Pul-
monary disease in polymyositis/dermatomyositis : 
a clinicopathological analysis of 65 autopsy cas-
es. Ann Rheum Dis, 46 : 23-29, 1987.
14. Kalluri M, Oddis CV. Pulmonary manifestations 
of the idiopathic inflammatory myopathies. Clin 
Chest Med, 31 : 501-512, 2010. 
15. Bouros D, Pneumatikos I, Tzouvelekis A. Pleural 
involvement in systemic autoimmune disor-
ders. Respiration, 75 : 361-371, 2008.
16. Arima K, Origuchi T, Tamai M, et al. RS3PE syn-
drome presenting as vascular endothelial growth 
factor associated disorder. Ann Rheum Dis, 
64 : 1653-1655, 2005.
17. Fujita K, Hatta K. Tufted angioma-like lesion as-
sociated with VEGF and IL-6 in TAFRO syn-
drome : Is it a common histological feature of mul-
ticentric Castleman disease/POEMS syndrome? J 
Cutan Pathol, 46 : 280-284, 2019. 
18. Kissel JT, Mendell JR, Rammohan KW. Microvas-
cular deposition of complement membrane attack 
complex in dermatomyositis. N Engl J Med, 
314 : 329-334, 1986.
19. Porcel JM, Ordi-Ros J, Esquerda A, et al. Antinu-
clear antibody testing in pleural fluid for the diag-
nosis of lupus pleuritis. Lupus, 16 : 25-27, 2007.
